These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 30819762)

  • 61. Discovery of Novel Indazole Derivatives as Highly Potent and Selective Human β3-Adrenergic Receptor Agonists with the Possibility of Having No Cardiovascular Side Effects.
    Wada Y; Shirahashi H; Iwanami T; Ogawa M; Nakano S; Morimoto A; Kasahara K; Tanaka E; Takada Y; Ohashi S; Mori M; Shuto S
    J Med Chem; 2015 Aug; 58(15):6048-57. PubMed ID: 26125514
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Attenuation of age-related muscle wasting and weakness in rats after formoterol treatment: therapeutic implications for sarcopenia.
    Ryall JG; Schertzer JD; Lynch GS
    J Gerontol A Biol Sci Med Sci; 2007 Aug; 62(8):813-23. PubMed ID: 17702871
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Regulation of endothelial permeability by beta-adrenoceptor agonists: contribution of beta 1- and beta 2-adrenoceptors.
    Zink S; Rösen P; Sackmann B; Lemoine H
    Biochim Biophys Acta; 1993 Sep; 1178(3):286-98. PubMed ID: 8103357
    [TBL] [Abstract][Full Text] [Related]  

  • 64. TLR2 activation causes tachyphylaxis to β2 -agonists in vitro and ex vivo: modelling bacterial exacerbation.
    Alkhouri H; Rumzhum NN; Rahman MM; FitzPatrick M; de Pedro M; Oliver BG; Bourke JE; Ammit AJ
    Allergy; 2014 Sep; 69(9):1215-22. PubMed ID: 24862376
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Desensitisation of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol.
    Scola AM; Chong LK; Suvarna SK; Chess-Williams R; Peachell PT
    Br J Pharmacol; 2004 Jan; 141(1):163-71. PubMed ID: 14662724
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Effects of beta(3)-adrenoceptor stimulation on prostaglandin E(2)-induced bladder hyperactivity and on the cardiovascular system in conscious rats.
    Takeda H; Yamazaki Y; Igawa Y; Kaidoh K; Akahane S; Miyata H; Nishizawa O; Akahane M; Andersson KE
    Neurourol Urodyn; 2002; 21(6):558-65. PubMed ID: 12382247
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Binding pockets of the beta(1)- and beta(2)-adrenergic receptors for subtype-selective agonists.
    Isogaya M; Sugimoto Y; Tanimura R; Tanaka R; Kikkawa H; Nagao T; Kurose H
    Mol Pharmacol; 1999 Nov; 56(5):875-85. PubMed ID: 10531390
    [TBL] [Abstract][Full Text] [Related]  

  • 68. No functional beta 3-adrenergic receptors expressed in rat skeletal muscle cells.
    Gao BB; Han QD
    Zhongguo Yao Li Xue Bao; 1998 Nov; 19(6):531-4. PubMed ID: 10437139
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Effects of formoterol and BRL 37344 on human umbilical arteries in vitro in normotensive and pre-eclamptic pregnancy.
    Karadas B; Kaya T; Cetin M; Parlak A; Durmus N; Bagcivan I; Gulturk S
    Vascul Pharmacol; 2007 May; 46(5):360-6. PubMed ID: 17229593
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Characterisation of beta2-adrenoceptors, using the agonist [11C]formoterol and positron emission tomography.
    Visser TJ; van Waarde A; Doze P; Elsinga PH; van der Mark TW; Kraan J; Ensing K; Vaalburg W
    Eur J Pharmacol; 1998 Nov; 361(1):35-41. PubMed ID: 9851539
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Characterization of the beta-adrenoceptor subtype involved in mediation of glucose transport in L6 cells.
    Nevzorova J; Bengtsson T; Evans BA; Summers RJ
    Br J Pharmacol; 2002 Sep; 137(1):9-18. PubMed ID: 12183326
    [TBL] [Abstract][Full Text] [Related]  

  • 72. β
    Luo J; Liu YH; Luo W; Luo Z; Liu CT
    Sci Rep; 2017 Jan; 7():39905. PubMed ID: 28051147
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Relationship between stereochemistry and the beta3-adrenoceptor agonistic activity of 4'-hydroxynorephedrine derivative as an agent for treatment of frequent urination and urinary incontinence.
    Tanaka N; Tamai T; Mukaiyama H; Hirabayashi A; Muranaka H; Ishikawa T; Kobayashi J; Akahane S; Akahane M
    J Med Chem; 2003 Jan; 46(1):105-12. PubMed ID: 12502364
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Selective activation of beta3-adrenoceptors by octopamine: comparative studies in mammalian fat cells.
    Carpéné C; Galitzky J; Fontana E; Atgié C; Lafontan M; Berlan M
    Naunyn Schmiedebergs Arch Pharmacol; 1999 Apr; 359(4):310-21. PubMed ID: 10344530
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammalian detrusor strips.
    Kanie S; Otsuka A; Yoshikawa S; Morimoto T; Hareyama N; Okazaki S; Kobayashi R; Hasebe K; Nakao K; Hayashi R; Mochizuki H; Matsumoto R; Ozono S
    Urology; 2012 Mar; 79(3):744.e1-7. PubMed ID: 22197203
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Characterization of adrenoceptor involvement in skeletal and cardiac myotoxicity Induced by sympathomimetic agents: toward a new bioassay for beta-blockers.
    Tan LB; Burniston JG; Clark WA; Ng Y; Goldspink DF
    J Cardiovasc Pharmacol; 2003 Apr; 41(4):518-25. PubMed ID: 12658052
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Budesonide prevents cytokine-induced decrease of the relaxant responses to formoterol and terbutaline, but not to salmeterol, in mouse trachea.
    Adner M; Larsson B; Säfholm J; Naya I; Miller-Larsson A
    J Pharmacol Exp Ther; 2010 Apr; 333(1):273-80. PubMed ID: 20061444
    [TBL] [Abstract][Full Text] [Related]  

  • 78. In vitro and in vivo preclinical profile of abediterol (LAS100977), an inhaled long-acting β2-adrenoceptor agonist, compared with indacaterol, olodaterol and vilanterol.
    Aparici M; Gavaldà A; Ramos I; Carcasona C; Otal R; Fernández-Blanco JA; Montero JL; García VM; López R; De Alba J; Doe C; Puig C; Vilella D; Miralpeix M
    Eur J Pharmacol; 2016 Jan; 770():61-9. PubMed ID: 26656755
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Autoantibodies against cardiac β(1)-adrenoceptor do not affect the low-affinity state β(1)-adrenoceptor-mediated inotropy in rat cardiomyocytes.
    Abdelkrim MA; Mallem MY; Chatagnon G; Gogny M; Desfontis JC; Noireaud J
    Can J Physiol Pharmacol; 2012 Apr; 90(4):407-14. PubMed ID: 22448877
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Influence of agonist intrinsic activity on the desensitisation of beta2-adrenoceptor-mediated responses in mast cells.
    Scola AM; Chong LK; Chess-Williams R; Peachell PT
    Br J Pharmacol; 2004 Sep; 143(1):71-80. PubMed ID: 15289287
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.